8-K: ADC Therapeutics Reports Positive Initial Data for ZYNLONTA in Marginal Zone Lymphoma and First Quarter 2024 Financial Results

ADC Therapeutics announced encouraging initial Phase 2 clinical trial data for ZYNLONTA in relapsed/refractory marginal zone lymphoma and reported first quarter 2024 financial results with a focus on hematology and pipeline advancement.

Summary

• ADC Therapeutics reported first quarter 2024 financial results, highlighting a 25% decrease in total operating expenses and a 16% decrease in adjusted total operating expenses compared to the same period last year.
• ZYNLONTA net sales reached $17.8 million in the first quarter of 2024, showing a 7% increase over the previous quarter but a 6% decrease compared to the first quarter of 2023.
• The company successfully completed the dose escalation phase of the LOTIS-7 trial and initiated the expansion phase, evaluating ZYNLONTA in combination with bispecific antibodies.
• Initial data from an investigator-initiated Phase 2 trial of ZYNLONTA in relapsed/refractory marginal zone lymphoma (MZL) showed a 93% complete response rate (13 out of 15 patients) and one partial response.
• The company's cash and cash equivalents were $234.3 million as of March 31, 2024, and they expect the cash runway to extend into the fourth quarter of 2025.
• Research and development expenses decreased to $25.7 million in the first quarter of 2024, compared to $38.4 million in the same period last year, due to reduced investment in camidanlumab tesirine and focused investment in prioritized programs.
• The company is advancing its solid tumor pipeline, with four lead candidates targeting Claudin-6, NaPi2b, PSMA, and ASCT2, with preclinical data showing promising anti-tumor activity.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with strong clinical data and cost reductions, although there are some concerns about revenue decline year-over-year and the company's cash burn. The positive clinical trial results and pipeline progress are very encouraging.

Positives

• ZYNLONTA sales showed sequential growth, increasing by 7% compared to the previous quarter.
• The company has significantly reduced operating expenses, with a 25% decrease in total operating expenses.
• The LOTIS-7 trial has progressed successfully, with no dose-limiting toxicities observed.
• The initial Phase 2 trial data for ZYNLONTA in MZL is very promising, with a high complete response rate.
• The company has a solid cash position, with a runway expected to last into the fourth quarter of 2025.
• The company is making progress in its solid tumor pipeline, with multiple candidates in development.
• The company has completed the dose escalation phase of the LOTIS-7 trial and initiated the expansion phase.

Negatives

• ZYNLONTA net sales decreased by 6% compared to the first quarter of 2023.
• The decrease in net sales was attributed to higher gross-to-net deductions and lower volume, partially offset by a higher price.
• The company reported a net loss of $46.6 million for the first quarter of 2024.
• The company's cash and cash equivalents decreased from $278.6 million at the end of 2023 to $234.3 million as of March 31, 2024.

Risks

• The company faces competition from new technologies and other pharmaceutical companies.
• The company's ability to grow ZYNLONTA revenue in the United States is subject to market acceptance and reimbursement coverage.
• The company's indebtedness could restrict its activities and require significant cash to service.
• The company's research and development projects and clinical trials are subject to risks and uncertainties.
• The company's ability to obtain regulatory approval for its products is subject to actions by the FDA and other regulatory authorities.
• The company's financial results are subject to fluctuations in the share price and other market conditions.

Future Outlook

The company expects to achieve commercial brand profitability for ZYNLONTA in 2024, complete enrollment in the LOTIS-5 trial in the second half of 2024, and complete Part 2 enrollment in the LOTIS-7 trial with an initial efficacy/safety update in the second half of 2024 and full data in the first half of 2025. They also anticipate additional data updates from the Phase 1 study of ADCT-601 and ADCT-602 in the second half of 2024.

Management Comments

• Ameet Mallik, Chief Executive Officer of ADC Therapeutics, stated that they were pleased to see continued progress from their corporate and capital allocation strategy focused primarily on hematology with ZYNLONTA while advancing their emerging solid tumor pipeline.
• Mr. Mallik also mentioned that they delivered sequential ZYNLONTA revenue growth and were encouraged by the initial IIT Phase 2 data with ZYNLONTA in MZL.

Industry Context

This announcement is significant in the context of the broader oncology market, where there is a high unmet need for effective treatments for relapsed/refractory lymphomas. The positive initial data for ZYNLONTA in MZL could position it as a valuable option in this space. The company's focus on advancing its ADC technology and pipeline aligns with the industry trend towards targeted therapies.

Comparison to Industry Standards

• The reported 93% complete response rate in the initial MZL trial data is significantly higher than the <30% CR rates observed with current NCCN preferred treatments for 2L+ MZL, such as those seen in the MAGNOLIA, AUGMENT, and GADOLIN trials.
• The LOTIS-7 trial's safety profile, with no dose-limiting toxicities and mostly low-grade CRS events, compares favorably to other combination therapies involving bispecific antibodies, which can often have higher rates of severe adverse events.
• The company's focus on next-generation ADC platforms and novel linker technology is in line with the industry's push for more effective and safer targeted therapies, similar to efforts by companies like Seagen and ImmunoGen.
• The company's cash runway extending into Q4 2025 is a positive sign, but it will need to continue to manage its expenses and generate revenue to maintain its financial stability, similar to other biotech companies in the clinical development stage.

Stakeholder Impact

• Shareholders may be positively impacted by the strong clinical data and cost reductions, but also concerned about the year-over-year revenue decline and cash burn.
• Employees may be affected by the cost-cutting measures, but also motivated by the progress in clinical trials and pipeline development.
• Patients may benefit from the potential of ZYNLONTA and other ADC candidates to provide effective treatment options.
• Creditors may be concerned about the company's indebtedness, but also reassured by the company's cash runway and progress in clinical trials.

Next Steps

• Complete enrollment in the LOTIS-5 trial in the second half of 2024.
• Complete Part 2 enrollment in the LOTIS-7 trial with an initial efficacy/safety update in the second half of 2024 and full data in the first half of 2025.
• Advance the solid tumor pipeline, with IND-enabling studies for NaPi2b and Claudin-6 targeting ADCs and drug candidate selection for PSMA and ASCT2 targeting ADCs.
• Provide additional data updates from the Phase 1 study of ADCT-601 and ADCT-602 in the second half of 2024.
• Expand the investigator-initiated trial in relapsed/refractory follicular lymphoma to 100 patients.
• Continue the investigator-initiated trial in relapsed/refractory marginal zone lymphoma with a target of 50 patients.

Key Dates

Keywords

ZYNLONTA, ADC Therapeutics, Antibody Drug Conjugate, Lymphoma, Marginal Zone Lymphoma, DLBCL, Clinical Trial, Hematology, Oncology, Financial Results, LOTIS-7, LOTIS-5, ADCT-601, ADCT-602